

A case report on filamin A gene mutation and progressive pulmonary disease in an infant

A lung tissue derived mesenchymal stem cell study

Valeria Calcaterra, MD^a, Maria Antonietta Avanzini, PhD^b, Melissa Mantelli, PhD^b, Emanuele Agolini, MD^c, Stefania Croce, PhD^b, Annalisa De Silvestri, PhD^d, Giuseppe Re, MD^e, Mirella Collura, MD^f, Alice Maltese, PhD^b, Antonio Novelli, MD^c, Gloria Pelizzo, MD^{g,*}

Abstract

Rationale: Mesenchymal stem cells (MSC) play a crucial role in both the maintenance of pulmonary integrity and the pathogenesis of lung disease. Lung involvement has been reported in patients with the filamin A (FLNA) gene mutation. Considering FLNA's role in the intrinsic mechanical properties of MSC, we characterized MSCs isolated from FLNA-defective lung tissue, in order to define their pathogenetic role in pulmonary damage.

Patient concerns: A male infant developed significant lung disease resulting in emphysematous lesions and perivascular and interstitial fibrosis. He also exhibited general muscular hypotonia, bilateral inguinal hernia, and deformities of the lower limbs (pes tortus congenitalis and hip dysplasia). Following lobar resection, chronic respiratory failure occurred.

Diagnosis: Genetic testing was performed during the course of his clinical care and revealed a new pathogenic variant of the FLNA gene c.7391_7403del; (p.Val2464AlafsTer5). Brain magnetic resonance imaging revealed periventricular nodular heterotopia.

Interventions and outcomes: Surgical thoracoscopic lung biopsy was performed in order to obtain additional data on the pathological pulmonary features. A small portion of the pulmonary tissue was used for MSC expansion. Morphology, immunophenotype, differentiation capacity, and proliferative growth were evaluated. Bone marrow-derived mesenchymal stem cells (BM-MSC) were employed as a control. MSCs presented the typical MSC morphology and phenotype while exhibiting higher proliferative capacity ($P < .001$) and lower migration potential ($P = .02$) compared to control BM-MSC.

Lessons: The genetic profile and altered features of the MSCs isolated from FLNA-related pediatric lung tissue could be directly related to defects in cell migration during embryonic lung development and pulmonary damage described in FLNA-defective patients.

Abbreviations: BM-MSC = bone marrow-derived mesenchymal stem cells, cPD = cumulative population doubling, FLNA = filamin A, MSC = mesenchymal stem cells, SDF = stromal cell-derived factor.

Keywords: children, filamin A, lung, mesenchymal stem cells, tissue

Editor: N/A.

VC and MAAs contributed equally to this work

The authors did not receive any funding from public, commercial or non-profit agencies to conduct this research.

The authors have no conflict of interests to declare.

^a Pediatric Unit, Department of Internal Medicine University of Pavia and Fondazione IRCCS Policlinico San Matteo, ^b Immunology and Transplantation Laboratory, Cell Factory, Pediatric Hematology Oncology Unit, Department of Maternal and Children's Health, Fondazione IRCCS Policlinico S. Matteo, Pavia, ^c Laboratory of Medical Genetics, Ospedale Pediatrico Bambino Gesù, Rome, ^d Biometry & Clinical Epidemiology, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, ^e Pediatric Anesthesiology and Intensive Care Unit, ^f Cystic Fibrosis and Respiratory Pediatric Center, ^g Pediatric Surgery Department, Children's Hospital, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy.

* Correspondence: Gloria Pelizzo, Pediatric Surgery Department, Children's Hospital, Via dei Benedettini n.1, 90134 Palermo, Italy (e-mail: gloriapelizzo@gmail.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2018) 97:50(e13033)

Received: 13 July 2018 / Accepted: 8 October 2018

<http://dx.doi.org/10.1097/MD.00000000000013033>

1. Introduction

Filamins are cytoskeletal proteins that organize actin filaments into networks and link these networks to cell membranes. Filamin A (FLNA) is the most abundant and widely-expressed protein among the 3 filamin isoforms. As a mediator of cytoskeleton reorganization, it regulates actin filament disassembly at the leading edge of motile cells and directs these filaments to the filopodia, lamellipodia, stress fibers and focal contacts. It is ubiquitously distributed, and null mutations have strong consequences on embryonic development in humans, with organ defects which suggest deficiencies in cell migration.^[1]

Recently lung involvement has been reported in patients with the FLNA gene mutation.^[2–9] The specific role of FLNA in the development of lung disease is still not fully understood. Many lung diseases are driven by the maladaptive proliferation of mesenchymal, epithelial, and endothelial cells, which results in dysfunctional lung remodeling.^[10]

Recent studies indicate that lung mesenchymal stem cells (MSCs) may contribute to lung injury and repair and to pulmonary disease progression.^[11] Considering FLNA's role in the intrinsic mechanical properties of MSC, including cell adhesion and migration, in this brief report, we characterized

MSCs isolated from *FLNA*-defective pediatric lung tissue in terms of morphology, phenotype, differentiation capacity, proliferative growth, and gene signature. These data should be useful in defining the role of MSCs in pulmonary damage described in *FLNA*-defective patients.

2. Material and methods

2.1. Ethical approval

This study was approved by the ethics committee of The Children's Hospital G. Di Cristina, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy

2.2. Consent statement

After written informed consent was obtained from the parents, a small portion of the pulmonary tissue destined for histological analysis was used for MSC expansion.

Informed consent was obtained from the parents for the publication of this study.

3. Methods

3.1. Isolation and culture

Isolation and expansion of MSCs from pulmonary tissue were performed following standard bone marrow culture procedures, as previously described.^[12,13] The pulmonary sample, after cutting into small pieces, was incubated in the presence of 1 mg/mL collagenase type II (Sigma Aldrich, Milan Italy) in α -MEM (Gibco, Milan Italy) at 37°C, 5% CO₂ for 30 minutes. Collagenase activity was blocked by adding α -MEM (Gibco) 10% FBS (Euroclone, Milan Italy) and the cell suspension was collected and plated in polystyrene culture flasks (Corning Costar, Corning, NY) at a density of 160,000/cm² in complete culture medium: D-MEM (Gibco) 10% FBS (Euroclone), gentamicin 50 mg/mL, and penicillin 100 U/mL.

Cultures were maintained at 37°C, 5% CO₂, and the medium was replaced twice a week. When MSCs reached $\geq 80\%$ confluence, they were harvested with Trypsin EDTA (Lonza, Milan, Italy) and replated for expansion at a density of 4000 cells/cm².

4. Characterization of ex-vivo expanded MSCs

4.1. Proliferative capacity

Proliferative capacity was defined as cumulative population doubling (cPD) calculated following the formula $PD = \log(n) / \log(n_0)$, where n is the number of harvested cells and n_0 is the number of seeded cells. Bone marrow-derived mesenchymal stem cells (BM-MSC) from healthy donors were employed as a control.

4.2. Immune phenotype

Cell immunophenotyping was performed by flow-cytometry. Fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal antibodies specific for CD73, CD34, CD90, CD14, CD45, CD31, CD105, HLA-I and HLA-DR and CXCR4 (Beckman Coulter, IL, Milan, Italy) were used. Appropriate, isotype-matched, non-reactive fluorochrome-conjugated antibodies were employed as controls. Cell populations were analyzed by direct immunofluorescence with a FACS Navios flow-cytometer (BC).

4.3. Differentiation capacity

The differentiation capacity of MSCs was assessed by incubating cells for at least 2 weeks at 37°C, 5% CO₂ in differentiation medium: α -MEM (Euroclone), 10% FBS, 10⁻⁷M dexamethasone, 50 mg/mL L-ascorbic acid and 5 mM β -glycerol phosphate (all from Sigma-Aldrich). For adipogenic differentiation 100 mg/mL insulin, 50 mM isobutyl methylxanthine, 0.5 mM indomethacin (Sigma-Aldrich), and 5 mM β -glycerol phosphate were also added. To detect osteogenic differentiation, cells were stained for alkaline phosphatase (AP) activity using Fast Blue (Sigma-Aldrich) and for calcium deposition with Alizarin Red (Sigma-Aldrich). Adipogenic differentiation was assessed based on the morphological appearance of fat droplets after staining with Oil Red O (Sigma-Aldrich).

4.4. Senescence assay

Cells were maintained in culture until they reached senescence. In order to reveal any change in morphology and/or proliferation rate, MSCs were closely monitored during senescence for up to 8 to 12 weeks before interrupting the cultures. Senescence of MSCs was assessed by staining with the β -galactosidase (SA- β -gal) staining Kit (Cell Signaling Technology, Danvers, MA), according to the manufacturer's instructions and evaluated by direct-light microscopy.

4.5. Migration assay

The cell migration assay was performed with the transwell migration chamber system (Merck Millipore, Milan, Italy), utilizing polycarbonate inserts with an 8 μ m pore size, as previously described.^[14] Briefly, 5×10^3 cells/well were seeded in the upper chambers of the 96-well plate. For each condition, the lower chambers were filled with 150 μ L of basal medium with or without stromal cell-derived factor (SDF). The cells were left to migrate for 16 hours at 37°C and 5% CO₂. At the end of the incubation, the underside of the membranes was fixed with 4% paraformaldehyde for 20 minutes. Cell nuclei were then stained with Hoechst 33258 (Life Technologies, Monza, Italy). Finally, the membranes were cut out and mounted onto glass slides with ProLong Gold antifade reagent (Life Technologies, Monza, Italy). Three replicates were evaluated for each condition. Images were acquired using an Olympus BX51 microscope (Olympus, Deutschland GmbH, Hamburg, Germany). The number of migrated cells was blindly-counted analyzing 15 random fields of the membranes per condition. Data were expressed as the means of the number of migrated cells \pm standard error (SE).

The number of migrated *FLNA*-MSCs was compared to the number of migrated BM-MSCs from healthy donors.

4.6. Genetic characterization

After obtaining informed consent for the genetic analyses, hybridization target enrichment and parallel sequencing were performed on genomic DNA extracted from pulmonary MSCs of the *FLNA*-defective patient. Sequences of the *FLNA* gene were enriched by using a custom NimbleGen SeqCap EZ Choice kit (Roche NimbleGen Inc., Madison, WI, USA) according to the manufacturer's protocol, and sequenced on the Illumina NextSeq550 platform. The BaseSpace pipeline (Illumina, <https://basespace.illumina.com/>) and the TGenxTM software (LifeMap Sciences) were used for the variant naming and

annotating variants, respectively. Sequencing data were aligned to the hg19 human reference genome.

4.7. Statistical analysis

Proliferative capacity of the patient's MSCs was compared with controls using the *z*-statistic, while the number of migrated cells was compared between the patient and controls with the *t* test for independent samples. Statistical significance was defined as a *P* value < .05. Data analyses were performed with the STATA statistical package (release 14.2, 2012, Stata Corporation, College Station, TX).

4.8. Case report

A male infant was referred to our surgical department, with a presumptive diagnosis of congenital lobar emphysema. He developed significant lung disease resulting in emphysematous lesions and perivascular and interstitial fibrosis. He also exhibited general muscular hypotonia, bilateral inguinal hernia, and deformities of the lower limbs (pes tortus congenitalis and hip dysplasia). Following lobar resection, chronic respiratory failure occurred, necessitating mechanical ventilation to assist the patient's breathing. The decision to perform a surgical thoracoscopic lung biopsy was made in order to obtain additional data on the pathological pulmonary features for prognostic predictions and therapeutic decisions.

Genetic testing was performed during the course of his clinical care and revealed a new pathogenic variant of the *FLNA* gene

c.7391_7403del; (p.Val2464AlafsTer5). Brain magnetic resonance imaging revealed periventricular nodular heterotopia.

A small portion (1 cm × 1 cm) of the pulmonary tissue obtained to lung biopsy was used for MSC expansion.

4.9. MSC expansion and characterization

Cells were isolated and expanded from pulmonary tissue of the *FLNA*-defective patient using the same standard culture conditions used for BM-MSC. The cells were plastic adherent, displayed the spindle shape morphology (Fig. 1A) and typical cell surface markers: positive for CD73, CD90, CD105, and HLA-I and negative for CD34, CD45, CD14, CD31 and HLA-DR. The percentage of cells expressing CXCR4 was >2% both in *FLNA*-MSCs and in BM-MSCs. While the *FLNA* MSC proliferative capacity, defined as cPD, was significantly higher (*P* < .00001) than BM-MSC, (Fig. 1B).

The in vitro osteogenic and adipogenic differentiation assays confirmed an osteogenic differentiation potential similar to BM-MSCs and lack of adipogenic differentiation capacity (Fig. 1C). Cells entered senescence phases at passage 14 (P14) (Fig. 1D). Considering these characteristics we defined these in vitro expanded cells from the patient's pulmonary tissue as lung-MSCs.

4.10. Migration assay

Since the *FLNA* mutation may lead to a defect in cell motility, we evaluated lung-MSC in vitro migration in comparison with BM-MSC. The results of the transwell migration assay reported as the




Figure 1. Panel A: MSCs expanded from pulmonary tissue of the *FLNA*-defective pediatric patient exhibiting the typical spindle-shaped morphology. Magnification 4X; Panel B: cPD of *FLNA*-MSC and BM-MSC cultured to passage (P)5 (continuous line *FLNA*-MSC, broken line BM-MSC); Panel C: Adipogenic and osteogenic differentiation capacity of BM-MSC and *FLNA*-MSCs. Differentiation into adipocytes, revealed by the formation of lipid droplets (stained with oil red O staining) present in control BM-MSC resulted absent in *FLNA*-MSC. Differentiation into osteoblasts, demonstrated by the histological detection of AP activity (purple reaction) and calcium deposition stained with Alizarin red staining, was similar in *FLNA*-MSC and BM-MSC. Magnification 10X; Panel D: β -gal staining of senescent *FLNA*-MSC at P14 (stained in blue). BM-MSC = bone marrow-derived mesenchymal stem cells, cPD = cumulative population doubling, *FLNA* = filamin A, MSC = mesenchymal stem cells.




Figure 2. Representative immunofluorescence staining of BM-MSC and FLNA-MSC after 16 hours of migration. A significantly reduced number of migrated cells was evident for FLNA-MSC compared with BM-MSC (blue = nuclei, scale bar = 200 μ m). BM-MSC = bone marrow-derived mesenchymal stem cells, FLNA = filamin A.

mean of the number of migrated cells per field, showed a significantly reduced number ($P = .026$) in lung-MSC compared with control BM-MSC (11.87 ± 2.54 and 37 ± 9.5 , respectively), Figure 2. No increases in cell migration were observed in wells filled with SDF supplemented medium for either lung-MSCs or control BM-MSC (9.0 ± 1.5 and 21.5 ± 5.3 , respectively).

4.11. Genetic characterization

DNA sequencing analysis of pulmonary MSCs confirmed the presence of the heterozygous frameshift variant, NM_001110556.1:c.7391_7403del; (p.Val2464AlafsTer5), in the *FLNA* gene, previously identified in the DNA from peripheral blood of the same patient (Fig. 3).

5. Discussion

To the best of our knowledge, this is the first report on a gene mutation in lung resident MSCs of an *FLNA*-defective patient. This mutation may be responsible for defective MSC migration and could have a causative role in the pulmonary damage described in these patients.

FLNA is a protein that crosslinks actin filaments into orthogonal networks in the cortical cytoplasm and participates in the anchoring of membrane proteins to the actin cytoskeleton establishing mechanical stability in cells.^[1] Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. The role of FLNA in cell migration is essential for embryonic development. More precisely, FLNA localizes to podosomes, which are cell structures involved in mesenchymal migration via adhesion and matrix degradation properties.^[15] Adhesion and migration of cells into tissues, including tissue-resident MSCs, are critical processes for organ formation, homeostasis, and repair. The organism's fitness is highly dependent on the appropriate function of tissue stem cells.^[16]

We demonstrated that MSCs isolated from *FLNA*-defective pediatric lung tissue, according to the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy Standards^[17], are plastic adherent when cultured under standard conditions, express the characteristic mesenchymal cell

surface antigens and have the capacity to differentiate into osteoblasts; however, adipocyte differentiation capacity was not detected. The differentiation tendencies of stem cells are closely linked to several factors including adhesive context, mechanical signals, and the physical responses of the cells.^[18] Cytoskeletal components composed of actin, microtubules, and intermediate filaments in the cytoplasm play an important role in the elastic properties of cells. These components vary in amount and arrangement during stem cell differentiation, resulting in changes in elasticity.^[19–21] Therefore, due to the influence of FLNA on the intrinsic mechanical properties of these cells, the role of an FLNA mutation in defective MSC differentiation cannot be excluded.

MSCs from *FLNA*-defective pediatric lung tissue exhibited a lower migration capacity compared to control BM-MSC. MSCs express a number of chemokine receptors that are likely involved in their migration capabilities,^[22] possibly in combination with growth factors and chemokines necessary for maximal effect.^[23] The contribution of the CXCL12 (SDF-1a)/CXCR4 axis to the recruitment of bone marrow-derived stem cells in lung pathologies has been demonstrated in a number of studies.^[24–26] The ability of MSCs to home and migrate appears to decrease during *in vitro* expansion also in relation to their loss of surface expression of chemokine receptors.^[27–28] Moreover, the similar CXCR4 expression in MSCs isolated from *FLNA*-defective tissue compared with control BM-MSC suggests that the reduced migration capability is probably not related to a chemokine/receptor mechanism, but may be linked to an FLNA deficiency. This alteration may be directly related to defects in cell migration during embryonic lung development and in pulmonary damage described in *FLNA*-defective patients.

The lung is a complex organ deriving from the endodermal and mesodermal germ line. Normal lung development depends on the well-orchestrated interaction between mesenchymal, epithelial, and endothelial cells. Even though genetic and epigenetic regulation, as well as the specialized intra-, inter-, and extracellular mechanisms responsible for proper development of the respiratory system continue to be elucidated, each step in lung development is reliant upon inductive cues and reciprocal interactions between the pulmonary epithelium and the surrounding mesenchyme. Loss of or abnormalities in cells and in their critical interactions can lead to




Figure 3. DNA sequencing analysis of pulmonary MSCs and peripheral blood of the patient. MSC=mesenchymal stem cells.

severe anatomical and functional defects in the airway and alveoli.^[29–32] MSC are key cells in the connective tissue hierarchy of many organs, including the lung, and given the intimate relationship between the epithelium and underlying mesenchyme in the lung, both during branching morphogenesis and in the adult it is likely that MSC play a crucial role in both the maintenance of epithelial integrity and pathogenesis of lung disease.^[31–32]

Even if a single case may represent a limit to the interpretation of the results, in our *FLNA*-defective patient, dysfunctional lung MSCs could have played a role in pathological lung development causing neonatal emphysematous lesions. Subsequently, they may limit repair, inducing dysfunctional matrix remodeling that results in the development of progressive fibrotic lung disease.

Due to their tissue-regenerative and immunomodulatory properties, MSCs have been proposed as cell therapy in lung disease associated with dysregulated immune responses (e.g., chronic inflammation in chronic pulmonary disease) and aberrant repair processes of lung tissue (e.g., idiopathic pulmonary fibrosis (IPF)). Results from preclinical studies using MSCs to treat the genetic syndrome, cystic fibrosis, have been reported.^[33] The potential therapeutic role of healthy BM-MSC cannot be excluded also in these defective patients.

In conclusion, we propose that dysfunctional *FLNA*-defective MSCs have a role in pulmonary damage as described in *FLNA*-

defective patients. Further studies are mandatory to improve our understanding of the role of MSCs in lung development and disease in genetic disorders, in order to propose prospective cell therapies.

Acknowledgments

The authors thank Dr L Kelly for English revision of the manuscript and Dr Elisa Lenta for technical support.

Author contributions

Conceptualization: Valeria Calcaterra, Maria Antonietta Avanzini, Gloria Pelizzo.

Data curation: Valeria Calcaterra, Maria Antonietta Avanzini.

Formal analysis: Annalisa De Silvestri.

Investigation: Melissa Mantelli, Emanuele Agolini, Stefania Croce, Giuseppe Re, Mirella Collura, Alice Maltese, Antonio Novelli.

Writing – original draft: Valeria Calcaterra, Maria Antonietta Avanzini, Melissa Mantelli, Emanuele Agolini, Antonio Novelli, Gloria Pelizzo.

Writing – review & editing: Valeria Calcaterra, Maria Antonietta Avanzini, Antonio Novelli, Gloria Pelizzo.

References

- [1] Stossel TP. Filamins and the potential of complexity. *Cell Cycle* 2010;9:1463.
- [2] Masurel-Paullet A, Haan E, Thompson EM, et al. Lung disease associated with periventricular nodular heterotopia and an FLNA mutation. *Eur J Med Genet* 2011;54:25–8.
- [3] Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. *Nat Cell Biol* 2004;6:1034–8.
- [4] Fox JW, Lamperti ED, Ekşioğlu YZ, et al. Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. *Neuron* 1998;21:1315–25.
- [5] Roberson S, Twigg S, Sutherland-Smith A, et al. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. *Nat Genet* 2003;33:487–91.
- [6] Sheen VL, Dixon PH, Fox JW, et al. Mutations in the X-linked filamin 1 gene cause periventricular nodular heterotopia in males as well as in females. *Hum Mol Genet* 2001;10:1775–83.
- [7] Sheen V, Jansen A, Chen M, et al. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. *Neurology* 2005;64:254–62.
- [8] de Wit M, Kros J, Halley D, et al. Filamin A mutation, a common cause for periventricular heterotopia, aneurysms and cardiac defects. *J Neurol Neurosurg Psychiatry* 2009;80:426–8.
- [9] de Wit MC, Tiddens HA, de Coe IF, et al. Lung disease in FLNA mutation: confirmatory report. *Eur J Med Genet* 2011;54:299–300.
- [10] Beers MF, Morrissey EE. The three R's of lung health and disease: repair, remodeling, and regeneration. *J Clin Invest* 2011;121:2065–73.
- [11] Foronjy RF, Majka SM. The potential for resident lung mesenchymal stem cells to promote functional tissue regeneration: understanding microenvironmental cues. *Cells* 2012;1:874–85.
- [12] Bernardo ME, Avanzini MA, Perotti C, et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. *J Cell Physiol* 2007;211:121–30.
- [13] Pelizzo G, Avanzini MA, Icaro Cornaglia A, et al. Mesenchymal stromal cells for cutaneous wound healing in a rabbit model: pre-clinical study applicable in the pediatric surgical setting 2015;13:219–33.
- [14] Coperchini F, Pignatti P, Carbone A, et al. TNF- α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer. *Tumour Biol* 2016;37:5569–75.
- [15] Guet R, Vérollet C, Lamsoul I, et al. Macrophage mesenchymal migration requires podosome stabilization by filamin A. *J Biol Chem* 2012;287:13051–62.
- [16] Kalinina NI, Sysoeva VY, Rubina KA, et al. Mesenchymal stem cells in tissue growth and repair. *Acta Naturae* 2011;3:30–7.
- [17] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–7.
- [18] Han I, Kwon BS, Park HK, et al. Differentiation potential of mesenchymal stem cells is related to their intrinsic mechanical properties. *Int Neurol J* 2017;21(suppl 1):S24–31.
- [19] Chen Q, Xiao P, Chen JN, et al. AFM studies of cellular mechanics during osteogenic differentiation of human amniotic fluid-derived stem cells. *Anal Sci* 2010;26:1033–7.
- [20] Yourek G, Hussain MA, Mao JJ. Cytoskeletal changes of mesenchymal stem cells during differentiation. *ASAIO J* 2007;53:219–28.
- [21] Rodríguez JP, González M, Ríos S, et al. Cytoskeletal organization of human mesenchymal stem cells (MSC) changes during their osteogenic differentiation. *J Cell Biochem* 2004;93:721–31.
- [22] Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* 2007;25:2739–49.
- [23] Ozaki Y, Nishimura M, Sekiya K, et al. Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. *Stem Cells Dev* 2007;16:119–29.
- [24] Xu J, Mora A, Shim H, et al. Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. *Am J Respir Cell Mol Biol* 2007;37:291–9.
- [25] Guo W, Li Z, Xie X, et al. Stromal cell-derived factor-1 α attenuates oleate-induced acute lung injury in rabbits. *Biochem Biophys Res Commun* 2014;452:191–6.
- [26] Shi H, Lu R, Wang S, et al. Effects of SDF-1/CXCR4 on acute lung injury induced by cardiopulmonary bypass. *Inflammation* 2017;40:937–45.
- [27] Honczarenko M, Le Y, Swierkowski M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. *Stem Cells* 2006;24:1030–41.
- [28] Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. *Leukemia* 2003;17:160–70.
- [29] Hass R, Kasper C, Böhm S, et al. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal* 2011;9:12–28.
- [30] Möbius MA, Rüdiger M. Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia. *Mol Cell Pediatr* 2016;3:18–24.
- [31] Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. *Respirology* 2013;18:397–411.
- [32] Hogan BL, Yingling JM. Epithelial/mesenchymal interactions and branching morphogenesis of the lung. *Curr Opin Genet Dev* 1998;8:481–6.
- [33] Borucki D, Gładysz D, Demkow U, et al. The Potential of Wharton's jelly derived mesenchymal stem cells in treating patients with cystic fibrosis. *Adv Exp Med Biol* 2015;833:23–9.